Benefits
Bioactive Coenzyme Form
Methylcobalamin is one of two metabolically active B12 forms in the body (along with adenosylcobalamin). Used directly by methionine synthase — bypasses the cyanocobalamin → methylcobalamin conversion step. Some practitioners prefer for sublingual supplementation.
Methionine Cycle / Homocysteine
Methylcobalamin is required cofactor for methionine synthase, which converts homocysteine to methionine using a methyl group from 5-MTHF. Low B12 → elevated homocysteine. Adequate B12 + folate + B6 maintains healthy homocysteine levels.
Neurological Function
B12 is critical for myelin synthesis and nerve function. Deficiency causes peripheral neuropathy, subacute combined degeneration of spinal cord, cognitive decline. Methylcobalamin specifically supports CNS B12-dependent reactions.
Vegetarian / Vegan Supplementation
B12 is found almost exclusively in animal foods. Vegans and strict vegetarians require supplementation to prevent deficiency. Methylcobalamin (along with cyanocobalamin) is bioavailable supplement option.
Elderly Absorption Decline
Stomach acid declines with age (atrophic gastritis affects ~10-30% of adults >50); intrinsic factor production may decline. Sublingual methylcobalamin bypasses gastric absorption requirement — useful when oral absorption is impaired.
Mechanism of action
Methionine Synthase Cofactor
Methylcobalamin transfers methyl group from 5-MTHF to homocysteine, generating methionine + tetrahydrofolate. Methionine becomes SAMe (S-adenosylmethionine) — the universal methyl donor for >100 methyltransferase reactions.
Adenosylcobalamin (Mitochondrial)
The OTHER active B12 form — adenosylcobalamin — is cofactor for methylmalonyl-CoA mutase in mitochondria; converts methylmalonyl-CoA to succinyl-CoA in propionate metabolism. Both methyl- and adenosyl-cobalamin needed; body interconverts.
Sublingual Absorption Pathway
Methylcobalamin sublingual lozenges may absorb directly through oral mucosa, bypassing gastric/intrinsic factor requirements. Evidence variable; oral high-dose B12 (1,000-2,000 µg) also effective via passive diffusion in pernicious anemia even without intrinsic factor.
Cyanocobalamin Conversion
Cyanocobalamin (most common synthetic supplement form) must be converted to methylcobalamin or adenosylcobalamin in cells. The 'cyano' group is released as harmless cyanide at minimal levels; major issue only with megadosing or very compromised liver function.
Clinical trials
Comparative bioavailability and tissue retention studies of methylcobalamin vs cyanocobalamin in B12-deficient and replete populations.
Healthy adults and B12-deficient patients.
Methylcobalamin shows slightly higher tissue retention in some studies; both forms effectively raise serum B12. For most clinical purposes, both forms work; methylcobalamin preferred by some practitioners for neurological/methylation contexts. Cyanocobalamin remains WHO standard for global supplementation.
Multiple RCTs of methylcobalamin (typically 1,500 µg/day) for diabetic peripheral neuropathy in Japan and elsewhere.
Type 2 diabetes patients with peripheral neuropathy.
Modest improvements in nerve conduction, paresthesias, neuropathic pain. Methylcobalamin is approved for peripheral neuropathy treatment in Japan. Western evidence base weaker. Standard diabetic neuropathy management includes glycemic control + duloxetine, pregabalin, gabapentin.
About this ingredient
Methylcobalamin is one of TWO METABOLICALLY ACTIVE forms of vitamin B12 (the other is adenosylcobalamin). Distinct from CYANOCOBALAMIN (synthetic, cheap, most common supplement form, requires conversion) and HYDROXOCOBALAMIN (longer-acting injectable form).
RDA: 2.4 µg/day adults; 2.6 µg pregnancy; 2.8 µg lactation.
UL: not established (low toxicity). Sources: animal foods (liver, fish, meat, dairy, eggs); plants do NOT contain B12 (vegans require supplementation or fortified foods). FUNCTIONS: (1) METHIONINE SYNTHASE cofactor — converts homocysteine to methionine using methyl group from 5-MTHF; supports SAMe / methylation; (2) (As adenosylcobalamin) METHYLMALONYL-CoA MUTASE cofactor — propionate metabolism. DEFICIENCY CAUSES: megaloblastic anemia, peripheral neuropathy, subacute combined degeneration, glossitis, fatigue, cognitive decline, dementia (in elderly), elevated homocysteine. POPULATIONS AT HIGH RISK: vegans/strict vegetarians, elderly (atrophic gastritis ~10-30% of adults >50), pernicious anemia (autoimmune intrinsic factor deficiency), post-bariatric surgery, chronic PPI/H2 blocker users, chronic metformin users, Crohn's disease/ileal resection.
EVIDENCE-BASED USES: (1) B12 deficiency repletion; (2) Vegan/vegetarian supplementation; (3) Elderly with absorption decline; (4) Metformin-associated B12 depletion; (5) Pernicious anemia (high-dose oral or injectable); (6) Diabetic peripheral neuropathy adjunct (Japan).
CRITICAL CAUTIONS: (1) FOLATE MASKING — high folate can MASK B12 deficiency anemia while neurological damage progresses; always check B12 status when supplementing folate; (2) NITROUS OXIDE (N2O) recreational use — INACTIVATES B12 and causes severe deficiency; chronic use causes spinal cord damage; (3) METFORMIN USERS — check B12 annually; supplementation usually appropriate after 4+ years of metformin; (4) PPI/H2 BLOCKER chronic users — same monitoring; (5) PERNICIOUS ANEMIA — high-dose oral B12 (1,000-2,000 µg) effective despite missing intrinsic factor (passive diffusion); injectable not always required; (6) PREGNANCY — adequate B12 important; deficiency linked to neural tube defects and infant developmental delays; (7) METHYLCOBALAMIN VS CYANOCOBALAMIN — for most clinical purposes both work; methylcobalamin preferred by some practitioners for neurological/methylation contexts; cyanocobalamin remains WHO standard; (8) HYDROXOCOBALAMIN — longer-acting injectable form preferred for cyanide poisoning treatment and some clinical contexts; (9) ROUTE — sublingual lozenges may bypass gastric absorption requirements; high-dose oral effective in most cases; injectable for severe deficiency or absorption failure.